AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
.jpg)
Highlights
- Certara (NASDAQ:CERT) is scheduled to release its next earnings figures after the market closes on Thursday, March 6th, with the figure for the period stated at 0.12 per share.
- The company’s stock has moved within a 52-week range from 9.41 to 19.87.
- The quick and current ratios are both at 2.86, reflecting solid liquidity.
Certara (NASDAQ:CERT) operates in the expanding biosimulation sector, which serves pharmaceutical and biotechnology organizations around the globe. Through advanced software and technology-enabled services, companies in this field streamline the development process for therapeutic products, accelerate regulatory reviews, and support informed decision-making in drug research.
Corporate Developments
Certara offers specialized software platforms that aid in drug discovery, preclinical work, clinical studies, and regulatory submissions. This suite of offerings is designed to optimize research and clinical pathways. By focusing on pharmacokinetics and pharmacodynamics, Certara’s platform helps diverse teams manage data efficiently. Its solutions have been employed to facilitate model-informed drug development, aiming to refine the overall approach to designing and testing innovative medical interventions.
Stock Performance
On the date of the most recent update, shares of Certara opened at around 12.33. Over the course of the past year, the company has experienced highs and lows within a broad range. The 50-day moving average price is near 12.39, while the 200-day moving average price hovers around 11.63. These observations reveal shifting market activity, with the stock’s value rising and falling in response to various external factors. Certara’s market capitalization stands at roughly 1.98 billion. The price-to-earnings-growth ratio is around 9.29, and the beta is 1.57.
Financial Metrics
Certara’s debt-to-equity ratio is approximately 0.28, which highlights a moderate approach to leveraging debt. A quick ratio of 2.86 and a current ratio of the same figure show the company’s capacity to meet immediate and short-term obligations. With a price-to-earnings ratio in negative territory, the valuation profile may attract attention from those examining earnings trends. These metrics underscore core aspects of the firm’s balance sheet, which may be monitored for shifts over time.
Earnings Overview
Certara is scheduled to publish its latest quarterly details after the market closes on March 6th. The announcement is set to feature a figure of 0.12 per share for the quarter. A link for the relevant conference call is expected to be accessible, enabling interested parties to learn more about the company’s performance. Updates from the event are commonly shared by various news and investor relations platforms, providing insight into Certara’s position within the broader biosimulation sector.
